Can patients at elevated risk of stroke treated with anticoagulants be further risk stratified?

Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 5.27

Should anticoagulation be resumed after intracerebral hemorrhage? Cleve Clin J Med (2010) 1.53

Bleeding and stroke risk in a real-world prospective primary prevention cohort of patients with atrial fibrillation. Chest (2011) 0.98

Safe use of antithrombotics for stroke prevention in atrial fibrillation: consideration of risk assessment tools to support decision-making. Ther Adv Drug Saf (2014) 0.89

Identifying a high stroke risk subgroup in individuals with heart failure. J Stroke Cerebrovasc Dis (2011) 0.86

CHADS 2 Scores in the Prediction of Major Adverse Cardiovascular Events in Patients with Cushing's Syndrome. Int J Endocrinol (2014) 0.81

International variation in use of oral anticoagulation among heart failure patients with atrial fibrillation. Am Heart J (2012) 0.81

Atrial fibrillation and thromboprophylaxis in heart failure: the need for patient-centered approaches to address adherence. Vasc Health Risk Manag (2013) 0.79

Antithrombotic therapy for the treatment of atrial fibrillation in the elderly. J Interv Card Electrophysiol (2009) 0.77

Predicting stroke risk in patients with atrial fibrillation. Stroke (2007) 0.75

Poor adherence to anticoagulation guidelines in patients with non-valvular atrial fibrillation treated in a tertiary cardiology unit. Heart Asia (2015) 0.75

A case-based approach to implementing guidelines for stroke prevention in patients with atrial fibrillation: balancing the risks and benefits. Thromb J (2015) 0.75

Can patients with atrial fibrillation be optimally risk stratified for stroke and thromboembolism? Stroke (2007) 0.75

Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med (2009) 18.03

Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med (2005) 8.77

Accuracy of ICD-9-CM codes for identifying cardiovascular and stroke risk factors. Med Care (2005) 7.73

A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med (2013) 7.09

Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study). J Am Coll Cardiol (2010) 5.07

CYP4F2 genetic variant alters required warfarin dose. Blood (2008) 4.23

Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet (2010) 3.55

Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA (2005) 3.54

Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Ann Intern Med (2009) 3.44

Recommendations for evaluation of prosthetic valves with echocardiography and doppler ultrasound: a report From the American Society of Echocardiography's Guidelines and Standards Committee and the Task Force on Prosthetic Valves, developed in conjunction with the American College of Cardiology Cardiovascular Imaging Committee, Cardiac Imaging Committee of the American Heart Association, the European Association of Echocardiography, a registered branch of the European Society of Cardiology, the Japanese Society of Echocardiography and the Canadian Society of Echocardiography, endorsed by the American College of Cardiology Foundation, American Heart Association, European Association of Echocardiography, a registered branch of the European Society of Cardiology, the Japanese Society of Echocardiography, and Canadian Society of Echocardiography. J Am Soc Echocardiogr (2009) 3.00

Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood (2010) 2.93

Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) Bleeding Score. Circulation (2009) 2.93

Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. Circulation (2011) 2.80

Influence of nitrous oxide anesthesia, B-vitamins, and MTHFR gene polymorphisms on perioperative cardiac events: the vitamins in nitrous oxide (VINO) randomized trial. Anesthesiology (2013) 2.39

Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation. JAMA (2005) 2.38

High-sensitivity cardiac troponin T in prediction and diagnosis of myocardial infarction and long-term mortality after noncardiac surgery. Am Heart J (2013) 2.30

Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype. Thromb Haemost (2005) 2.25

Genetic-based dosing in orthopedic patients beginning warfarin therapy. Blood (2007) 2.23

Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol (2010) 2.00

Analysis of cause-specific mortality in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Circulation (2004) 1.99

Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J (2011) 1.98

Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation (2010) 1.96

Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. BMJ (2011) 1.74

Statistical design of personalized medicine interventions: the Clarification of Optimal Anticoagulation through Genetics (COAG) trial. Trials (2010) 1.72

Cost-effectiveness of outpatient cardiac monitoring to detect atrial fibrillation after ischemic stroke. Stroke (2010) 1.71

Preference-based antithrombotic therapy in atrial fibrillation: implications for clinical decision making. Med Decis Making (2005) 1.68

Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO Study. Circulation (2012) 1.62

Percutaneous pacemaker and implantable cardioverter-defibrillator lead extraction in 100 patients with intracardiac vegetations defined by transesophageal echocardiogram. J Am Coll Cardiol (2010) 1.58

Can we rely on RE-LY? N Engl J Med (2009) 1.58

Effects of phosphodiesterase type 5 inhibition on systemic and pulmonary hemodynamics and ventricular function in patients with severe symptomatic aortic stenosis. Circulation (2012) 1.56

Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation. Stroke (2006) 1.53

Use of EPO in critically ill patients with acute renal failure requiring renal replacement therapy. Am J Kidney Dis (2005) 1.49

Implantable cardioverter-defibrillator therapy improves long-term survival in patients with unexplained syncope, cardiomyopathy, and a negative electrophysiologic study. Heart Rhythm (2005) 1.48

Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes). JACC Cardiovasc Interv (2013) 1.46

Genetic warfarin dosing: tables versus algorithms. J Am Coll Cardiol (2011) 1.43

Validation of claims-based diagnostic and procedure codes for cardiovascular and gastrointestinal serious adverse events in a commercially-insured population. Pharmacoepidemiol Drug Saf (2010) 1.43

Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy. Thromb Haemost (2011) 1.35

Cost-effectiveness of extending Medicare coverage of immunosuppressive medications to the life of a kidney transplant. Am J Transplant (2004) 1.33

Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation (2011) 1.33

Comorbidity indices to predict mortality from Medicare data: results from the national registry of atrial fibrillation. Med Care (2005) 1.31

Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials. Am Heart J (2006) 1.21

Predictors of mortality in younger and older patients with heart failure and preserved or reduced left ventricular ejection fraction. Am Heart J (2003) 1.19

Performance of commercial platforms for rapid genotyping of polymorphisms affecting warfarin dose. Am J Clin Pathol (2008) 1.17

Dissecting intramyocardial hematoma: clinical presentation, pathophysiology, outcomes and delineation by echocardiography. Echocardiography (2008) 1.14

ST-elevation acute coronary syndromes in the Platelet Inhibition and Patient Outcomes (PLATO) trial: insights from the ECG substudy. Circulation (2011) 1.13

Rationale and design of the Clarification of Optimal Anticoagulation through Genetics trial. Am Heart J (2013) 1.12

Clinical Benefit of American College of Chest Physicians versus European Society of Cardiology Guidelines for Stroke Prophylaxis in Atrial Fibrillation. J Gen Intern Med (2015) 1.12

Anemia does not predict mortality in elderly patients with heart failure. Am J Geriatr Cardiol (2007) 1.11

Predictors of heart failure in patients with stable coronary artery disease: a PEACE study. Circ Heart Fail (2009) 1.04

An invasive strategy is associated with decreased mortality in patients 80 years and older with acute myocardial infarction. Am J Geriatr Cardiol (2007) 1.03

Risk factors, echocardiographic patterns, and outcomes in patients with acute ventricular septal rupture during myocardial infarction. Am J Cardiol (2005) 1.03

Optimal initial dose adjustment of warfarin in orthopedic patients. Ann Pharmacother (2007) 1.03

Gamma-glutamyl carboxylase and its influence on warfarin dose. Thromb Haemost (2010) 1.02

Effect of warfarin nonadherence on control of the International Normalized Ratio. Am J Health Syst Pharm (2004) 1.01

Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin: assessment of incidence, case-fatality rate, time course and sites of bleeding, and risk factors for bleeding. Arch Intern Med (2006) 0.99

Reliability for grading acute rejection and airway inflammation after lung transplantation. J Heart Lung Transplant (2005) 0.98

American Heart Association atrial fibrillation research summit: a conference report from the American Heart Association. Circulation (2011) 0.97

The analysis of bleeding risk-prediction scores should include all major bleeds. J Am Coll Cardiol (2013) 0.97

Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial. Circ Cardiovasc Qual Outcomes (2012) 0.96

Prior smoking status, clinical outcomes, and the comparison of ticagrelor with clopidogrel in acute coronary syndromes-insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J (2012) 0.96

Cost of dabigatran for atrial fibrillation. BMJ (2011) 0.94

Physician and nurse acceptance of technicians to screen for geriatric syndromes in the emergency department. West J Emerg Med (2011) 0.94

The pharmacogenetics of coumarin therapy. Pharmacogenomics (2005) 0.93

The management of anticoagulants in the periendoscopic period for patients with atrial fibrillation: a decision analysis. Am J Med (2004) 0.92

Interactive modeling for ongoing utility of pharmacogenetic diagnostic testing: application for warfarin therapy. Clin Chem (2009) 0.90

Cystatin C and estimated glomerular filtration rate as predictors for adverse outcome in patients with ST-elevation and non-ST-elevation acute coronary syndromes: results from the Platelet Inhibition and Patient Outcomes study. Clin Chem (2011) 0.90

Use of pharmacogenetics to guide warfarin therapy. Drugs Today (Barc) (2004) 0.90

Students' expectations when entering an interprofessional master's degree program for health professionals: a qualitative study. J Allied Health (2013) 0.88

Genotype and risk of major bleeding during warfarin treatment. Pharmacogenomics (2014) 0.88

A comparison of the human papillomavirus test and Papanicolaou smear as a second screening method for women with minor cytological abnormalities. Acta Obstet Gynecol Scand (2005) 0.87

Risk factors for bleeding in patients taking coumarins. Curr Hematol Rep (2002) 0.85

Three-dimensional echocardiography of the right atrial embryonic remnants. Am J Cardiol (2002) 0.85

Pharmacogenomics of HIV therapy: summary of a workshop sponsored by the National Institute of Allergy and Infectious Diseases. HIV Clin Trials (2011) 0.84

Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery. J Am Coll Cardiol (2012) 0.84

Anemia: an independent predictor of death and hospitalizations among elderly patients with atrial fibrillation. Am Heart J (2009) 0.84

Substitution of generic warfarin for Coumadin in an HMO setting. Ann Pharmacother (2002) 0.84

Warfarin dose reduction vs watchful waiting for mild elevations in the international normalized ratio. Chest (2003) 0.83

Localization of a coronary artery fistula using contrast transesophageal echocardiography. J Am Soc Echocardiogr (2002) 0.83

Placenta percreta with invasion of the bladder wall: management with a multi-disciplinary approach. J Clin Anesth (2010) 0.82

A dedicated investigation unit improves management of syncopal attacks (Syncope Study of Unselected Population in Malmo--SYSTEMA I). Europace (2010) 0.82

Cost-savings analysis of using a portable coagulometer for monitoring homebound elderly patients taking warfarin. Am J Geriatr Cardiol (2003) 0.81

Yield of surveillance bronchoscopy for acute rejection and lymphocytic bronchitis/bronchiolitis after lung transplantation. J Heart Lung Transplant (2004) 0.81

Tolerability, pharmacokinetics, and pharmacodynamics of the glucokinase activator AZD1656, after single ascending doses in healthy subjects during euglycemic clamp. Int J Clin Pharmacol Ther (2012) 0.81

Cystatin C- and creatinine-based estimates of renal function and their value for risk prediction in patients with acute coronary syndrome: results from the PLATelet Inhibition and Patient Outcomes (PLATO) study. Clin Chem (2013) 0.81

Improving adherence to coronary heart disease secondary prevention medication guidelines at a community hospital. AMIA Annu Symp Proc (2006) 0.80

Fifteen-year risk of major coronary events predicted by Holter ST-monitoring in asymptomatic middle-aged men. Eur J Cardiovasc Prev Rehabil (2005) 0.80

Detection of coronary artery disease with perfusion stress echocardiography using a novel ultrasound imaging agent: two Phase 3 international trials in comparison with radionuclide perfusion imaging. Eur J Echocardiogr (2009) 0.80

Sudden cardiac death in patients with stable coronary artery disease and preserved left ventricular systolic function. Am J Cardiol (2008) 0.79

Pediatric warfarin practice and pharmacogenetic testing. Thromb Res (2010) 0.78

Admission international normalized ratio levels, early treatment strategies, and major bleeding risk among non-ST-segment-elevation myocardial infarction patients on home warfarin therapy: insights from the National Cardiovascular Data Registry. Circulation (2012) 0.78

Removal of virus from boar semen spiked with porcine circovirus type 2. Anim Reprod Sci (2011) 0.77

ACP Journal Club. Various risk stratification schemes predict ischemic stroke and bleeding in atrial fibrillation. Ann Intern Med (2012) 0.77

Speech recognition in noise using bilateral open-fit hearing aids: the limited benefit of directional microphones and noise reduction. Int J Audiol (2012) 0.77

Assessment of myocardial perfusion during pharmacologic contrast stress echocardiography. Am J Cardiol (2002) 0.77

Is primary care ready for pharmacogenetics? Pharmacogenomics (2006) 0.76

Trials and tribulations of noninferiority: the ximelagatran experience. J Am Coll Cardiol (2006) 0.75

No effects on myocardial ischaemia in patients with stable ischaemic heart disease after treatment with ramipril for 6 months. Curr Control Trials Cardiovasc Med (2001) 0.75

A systematic analysis and comparison of warfarin initiation strategies. Pharmacogenet Genomics (2016) 0.75

In reply. Anesthesiology (2014) 0.75

Improving Prediction of Postoperative Myocardial Infarction With High-Sensitivity Cardiac Troponin T and NT-proBNP. Anesth Analg (2016) 0.75